Anti-Albuminuric Effects of Spironolactone In Type-2 Diabetic Nephropathy

@inproceedings{Giri2019AntiAlbuminuricEO,
  title={Anti-Albuminuric Effects of Spironolactone In Type-2 Diabetic Nephropathy},
  author={Dr. Richa Giri and Dr. Ashish Naresh and Dr. J. S. Kushwaha and Dr. Brijesh Kumar and Dr. Kuldeep Verma and Dr. Mohommed Imran and M. A. Khan},
  year={2019}
}
  • Dr. Richa Giri, Dr. Ashish Naresh, +4 authors M. A. Khan
  • Published 2019
Original Research Article Background: The study was conducted to evaluate the protective effects of Spironolactone on diabetics (30-70yr) in relation to proteinuria and state of Diabetic Nephropathy. Material methods: A comparative, prospective, nonrandomized, non-blinded experimental study was conducted on 32 patients (30-70yr) of diagnosed Type 2 Diabetes Mellitus showing proteinuria. Total duration of study was about one year from October 2017 to October 2018. Subjects were followed over 12… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2008
VIEW 1 EXCERPT

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2005